Novocure Shares Rise 17% After FDA Accepts Pre-Market Application
By Ben Glickman
Shares of Novocure rose Thursday after U.S. regulators accepted a pre-market application for the company's lung-cancer therapy.
The stock was up 17% to $14.52 in recent trading. Shares are down 63% in the last six months.
The Root, Switzerland-based cancer-treatment developer said Thursday that the U.S. Food and Drug Administration had accepted its Premarket Approval application for the use of Tumor Treating Fields therapy to treat non-small cell lung cancer.
Novocure is expecting a decision from the FDA in the second half of 2024.
The company's trial data, which was submitted to the FDA for review, tested the safety and effectiveness of TTFields therapy in combination with standard systemic therapies in treating NSCLC following progression after receiving platinum-based therapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 10:55 ET (15:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy